Fluocinolone acetonide micro-insert intravitreous implant - pSivida

Drug Profile

Fluocinolone acetonide micro-insert intravitreous implant - pSivida

Alternative Names: DF-277; Durasert™ three-year uveitis insert; FAI insert; Fluocinolone; Fluocinolone acetonide intravitreal insert; Iluvien; Injectable micro-insert - pSivida; Medidur; Medidur-FA; NSC-92339; Ophthalmic implant - Alimera Sciences/pSivida

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator pSivida Inc
  • Developer Alimera Sciences; Johns Hopkins University; pSivida Inc
  • Class Anti-inflammatories; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Glucocorticoid receptor agonists; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Uveitis

Highest Development Phases

  • Marketed Diabetic macular oedema
  • Phase III Uveitis
  • No development reported Dry age-related macular degeneration; Retinal vascular occlusion; Wet age-related macular degeneration

Most Recent Events

  • 08 May 2017 Efficacy data from a phase III trial in Uveitis released by pSivida
  • 04 May 2017 Fluocinolone acetonide micro-insert intravitreous implant - pSivida is available for licensing in European Union as of 04 May 2017. http://www.psivida.com/products.html
  • 04 May 2017 pSivida announces its intention to submit the European Market Authorization Application (MAA) for Uveitis in June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top